Tarius SAC Tracker®
The full report for this meeting has been sent to subscribers by email. Interested in subscribing?
Results Wire: US FDA Advisory Committee Votes Narrowly Against Approval of Jatenzo, a Proposed Oral Testosterone Replacement Therapy by Clarus Therapeutics – JAN 9, 2018 (BRUDAC)
This SAC Tracker report is only available for SAC Tracker subscribers.
The SAC Tracker Reports is available for FREE on this site until 10 days after the meeting is held.
To obtain unlimited access to all SAC Tracker meeting reports back to 2010 and onwards, including the committee members' voting history, you must subscribe to the SAC Tracker service.
DISCLAIMER: The information in this document is for informational purposes only. Tarius A/S assumes no liability for any inaccurate or incomplete information, or for any actions taken in reliance thereon. © Tarius A/S. All rights reserved.